Enpicom, a software engineering company, has closed a capital investment round led by BOP Capital. With this, the company can support its SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. The additional funds enable the company to scale at a faster pace and develop product extensions for improved antibody discovery, characterisation, and development.
The company’s platform is a cloud solution designed to improve immunogenomics research by guiding the discovery and development of biotherapeutics. Tailored to the needs of scientists working in antibody discovery, it offers an environment to combine and manage sequencing data derived from sequencing technologies (e.g., Sanger, bulk NGS, and Single Cell), integrate assay data from wet-lab experiments, and predict exposed sequence liabilities. All this information can be incorporated into tailored analysis workflows to support candidate selection and prioritisation.
"We are thrilled with this capital injection to further grow our business. It clearly illustrates the trust of our existing investor group, BOM Brabant Ventures, NextGen Ventures, and Arches Capital, in our team and proposition. With the addition of BOP Capital, we have a great new strategic investor on board." said Jos Lunenberg, CEO at Enpicom.
"BOP Capital is very proud to join Enpicom’s investor base. We believe in impact through technology. This is exactly what we see in Enpicom’s platform. In combination with exceptional leadership and a strong execution track record, this provides a perfect setup to realise future growth in a highly promising market. We are looking forward to becoming part of their journey and work closely with the Enpicom team in the coming years." said Jeroen Mensen, Managing Partner at BOP Capital.
